Penumbraの空売り状況は、投資家がPenumbraの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Penumbra (NYSE:PEN) 株価情報, 空売り情報

PENUMBRA INC

Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Penumbra Inc

Pendle - United States Dollar

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions Inc

Peninsula Energy Ltd

PENINSULA ENERGY LTD by Peninsula Energy Ltd.

PENN Entertainment Inc

PENTAMASTER CORP BHD by PENTAMASTER CORP BHD.

PENNANT INTL GRP PLC by Pennant International Group PLC

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 19.16% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484619_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.07%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Penumbra's Recent Short Interest

In the preceding three months, 14 analysts have released ratings for Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Penumbra and provided 12-month price targets. The average target is $306.86, accompanied by a high estimate of $340.00 and a low estimate of $260.00. Surpassing the previous average price target of $273.91, the current average has increased by 12.03%.
<img src="https://www.benzinga.com/files/images/story/2025/1741978869_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$320.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$313.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$328.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Penumbra. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Penumbra's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Penumbra analyst ratings.</a>
<h2>Get to Know Penumbra Better</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
<h3>Penumbra: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Penumbra displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.99%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Penumbra's ROA excels beyond industry benchmarks, reaching 2.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Penumbra's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Penumbra Stock

WIIM

Penumbra shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a price target of $320.

B of A Securities analyst Travis Steed initiates coverage on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy rating and announces Price Target of $320.

News

Price Target

Initiation

B of A Securities Initiates Coverage On Penumbra with Buy Rating, Announces Price Target of $320

Penumbra Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is trading higher after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/02/n43796948/penumbra-inc-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">fourth-quarter earnings</a>.
The medical device company reported:
<ul>
<li>Adjusted EPS of 97 cents, up from 76 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 90 cents</a>.</li>
<li>Sales of $315.52 million, up 10.8% year over year and beating the consensus of $311.55 million.</li>
<li>Global thrombectomy product Q4 sales grew to $220.1 million, an increase of 15.4% in reported and constant currency</li>
<li>U.S. thrombectomy product sales increased by 27.3%.</li>
<li>Global embolization and access product revenues grew to $95.4 million in the fourth quarter of 2024, an increase of 1.6%, or 1.5% in constant currency</li>
<li>U.S. embolization and access product revenue increased by 8.9%.</li>
<li>Operating income reached $42.8 million, with an adjusted&nbsp;operating income of $48.6 million&nbsp;in the fourth quarter of 2024.</li>
<li>Q4 net income reached $33.7 million, and adjusted EBITDA was $63.7 million, with margins of 10.7% and 19.8%, respectively.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42534137/penumbra-is-poised-to-gain-share-in-an-expanding-market-says-bullish-analyst" rel="noreferrer noopener">Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst</a>
<h2 class="wp-block-heading">Penumbra Guidance</h2>
The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion.
Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, driven primarily by its computer-assisted vacuum thrombectomy products.
The company also expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13% to 14% of revenue for 2025.
Analyst reactions:
<ul>
<li>Baird maintains the Outperform rating on Penumbra, raising the price target <a href="https://www.benzinga.com/quote/PEN/analyst-ratings" target="_blank" rel="noreferrer noopener">from $305 to $328</a>.</li>
<li>Needham reiterates Penumbra&#8217;s Hold rating.</li>
<li>Morgan Stanley maintains Penumbra with an Equal-Weight, raising the price target from $240 to $260.</li>
<li>Piper Sandler reiterates Penumbra with an Overweight, increasing the price target from $250 to $330.</li>
<li>Wells Fargo also reaffirms Penumbra&#8217;s Overweight rating, with a price target of $305, up from $275.</li>
<li>UBS analyst maintains Penumbra with a Buy and raises the price target from $305 to $320.</li>
<li>Canaccord Genuity maintains the Buy rating on Penumbra and raises the price target from $323 to $340.</li>
<li>Truist Securities reaffirms the Buy rating for Penumbra and raises the price target from $285 to $325.</li>
<li>RBC Capital maintains Penumbra with an Outperform rating and raises the price target from $285 to $313.</li>
<li>JP Morgan maintains Penumbra with an Overweight rating and raises the price target from $230 to $285.</li>
</ul>
Price Action: Penumbra stock is up 11.3% at $301.89 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" target="_blank" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

General

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

U.S. stocks were lower, with the Dow Jones falling over 200 points on Wednesday.
Shares of Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and FY25 outlook. It also recommended <a href="https://in.benzinga.com/25/02/43812509/garmin-q4-earnings-wearables-and-adventure-watches-drive-growth-raises-dividend-20-projects-68-billion-revenue-for-2025">20% dividend hike</a>.
Garmin reported fiscal fourth-quarter 2024 revenue growth of 23% year-on-year to $1.82 billion, beating the analyst consensus estimate of $1.70 billion. The GPS navigation and wearable technology company's proforma EPS of $2.41 beat the analyst consensus estimate of $2.03.
Garmin shares jumped 14.3% to $245.41 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) shares jumped 61.3% to $49.21.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) gained 26.4% to $21.40 after the company reported better-than-expected fourth-quarter sales results and issued first-quarter revenue guidance with its midpoint above estimates.</li>
<li>Compass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) surged 23.8% to $9.89 after the company reported better-than-expected fourth-quarter revenue results and issued first-quarter revenue guidance above estimates.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 22.6% to $71.75 after the company announced plans to introduce at-home lab testing through its platform. Also, Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $38 to $68.</li>
<li>The Andersons, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANDE#NASDAQ">ANDE</a>) rose 21.1% to $49.38 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Appian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) gained 20.8% to $38.69 after the company reported better-than-expected quarterly EPS and revenue.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 15.5% to $64.47 on possible continued momentum from last week. Investors await an update from the company regarding its delayed filing.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 14.4% to $33.46 after Scotiabank initiated coverage on the stock with a Sector Outperform rating and announced a $102 price target.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 14.4% to $3.8350 after the company announced it received FDA authorization for an expanded access program offering alternative source of BCG for bladder cancer patients.</li>
<li>Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) rose 13.2% to $306.92 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) gained 8.8% to $37.97 following upbeat quarterly earnings.</li>
<li>RB Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) rose 8.8% to $105.06 following better-than-expected fourth-quarter financial results.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) gained 7.7% to $62.36 after the company announced the introduction of its Mplab AI coding assistant, which leverages the power of AI to assist software developers and engineers in writing and debugging code.</li>
<li>Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) gained 7.3% to $236.22 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) rose 5.8% to $51.70 following upbeat earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43811979/top-3-financial-stocks-that-may-collapse-in-q1">Top 3 Financial Stocks That May Collapse In Q1</a></li>
</ul>

Markets

ANDE

APPN

ATGL

COMP

GRMN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IBRX

MCHP

SEDG

SMCI

VKTX

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday

JP Morgan analyst Robert Marcus maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $230 to $285.

JP Morgan Maintains Overweight on Penumbra, Raises Price Target to $285

Truist Securities analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $285 to $325.

Truist Securities Maintains Buy on Penumbra, Raises Price Target to $325

RBC Capital analyst Shagun Singh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $285 to $313.

RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $313

Canaccord Genuity analyst Jason Mills maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $323 to $340.

Canaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $340

UBS analyst Priya Sachdeva maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $305 to $320.

UBS Maintains Buy on Penumbra, Raises Price Target to $320

Wells Fargo analyst Larry Biegelsen maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $275 to $305.

Wells Fargo Maintains Overweight on Penumbra, Raises Price Target to $305

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $250 to $330.

Reiteration

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $330

Penumbra shares are trading higher after Baird and Morgan Stanley raised their respective price targets on the stock.

Morgan Stanley analyst Kallum Titchmarsh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Equal-Weight and raises the price target from $240 to $260.

Morgan Stanley Maintains Equal-Weight on Penumbra, Raises Price Target to $260

Needham analyst Mike Matson reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) from Hold to Hold.

Needham Reiterates Hold on Penumbrato Hold

Baird analyst David Rescott maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $305 to $328.

Baird Maintains Outperform on Penumbra, Raises Price Target to $328

Penumbra shares are trading higher after the company reported Q4 earnings and revenue above estimates.

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) sees FY2025 sales of $1.340 billion-$1.360 billion vs $1.36 billion analyst estimate.

Penumbra Sees FY2025 Sales $1.340B-$1.360B vs $1.36B Est

Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.90 by 7.78 percent. This is a 27.63 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $315.52 million which beat the analyst consensus estimate of $311.55 million by 1.27 percent. This is a 10.83 percent increase over sales of $284.68 million the same period last year.

Earnings Beats

Penumbra Q4 Adj $0.97 Beats $0.90 Estimate, Sales $315.52M Beat $311.55M Estimate

Press Releases

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Penumbra, Inc. Reports Third Quarter 2024 Financial Results

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Comments

Penumbra

空売り

Penumbra (NYSE:PEN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル